

1 Viral RNA load in plasma is associated with critical illness and a dysregulated host 2 response in COVID-19.

3 Jesús F Bermejo-Martin^{1,2,3*}, Milagros González-Rivera^{4,5 *}, Raquel Almansa^{1,2,3*}, Dariela
4 Micheloud^{6*}, Ana P. Tedim^{1,2*}, Marta Domínguez-Gil^{7*}, Salvador Resino^{8*}, Marta
5 Martín-Fernández^{1,2}, Pablo Ryan Murua⁹, Felipe Pérez-García¹⁰, Luis Tamayo^{1,11}, Raúl
6 Lopez-Izquierdo¹², Elena Bustamante¹³, César Aldecoa^{1,14,15}, José Manuel Gómez¹⁶, Jesús
7 Rico-Feijoo^{1,15}, Antonio Orduña¹⁷, Raúl Méndez¹⁸, Isabel Fernández Natal¹⁹, Gregoria
8 Megías²⁰, Montserrat González-Estecha^{4,5}, Demetrio Carriedo²¹, Cristina Doncel^{1,2,3},
9 Noelia Jorge^{1,2,3}, Alicia Ortega^{1,2,3}, Amanda de la Fuente^{1,2,3}, Félix del Campo²², José
10 Antonio Fernández-Ratero²³, Wysali Trapiello²⁴, Paula González-Jiménez¹⁸, Guadalupe
11 Ruiz²⁴, Alyson A. Kelvin^{25,26}, Ali Toloue Ostadgavahi^{25,26}, Ruth Oneizat⁷, Luz María
12 Ruiz⁷, Iria Miguéns⁶, Esther Gargallo⁶, Ioana Muñoz⁶, Sara Pelegrin¹⁵, Silvia Martín^{1,15},
13 Pablo García Olivares¹⁶, Jamil Antonio Cedeño¹⁶, Tomás Ruiz Albi²², Carolina Puertas⁴,
14 Jose Ángel Berezo^{1,11}, Gloria Renedo¹³, Rubén Herrán^{1,11}, Juan Bustamante-Munguira²⁷,
15 Pedro Enríquez¹¹, Ramón Cicuendez¹³, Jesús Blanco¹¹, Jessica Abadia²⁸, Julia Gómez
16 Barquero²⁸, Nuria Mamolar¹³, Natalia Blanca-López⁹, Luis Jorge Valdivia²¹, Belén
17 Fernández Caso¹⁹, María Ángeles Mantecón²⁰, Anna Motos^{3,29}, Laia Fernandez-Barat^{3,29},
18 Ricard Ferrer^{3,30}, Ferrán Barbé^{3,31}, Antoni Torres^{3,29} ^Δ, Rosario Menéndez^{3,18} ^Δ, José María
19 Eiros⁷ ^Δ, David J Kelvin^Δ ^{25,26}.

20 * These authors contributed equally

21 ^Δ These authors contributed equally

22

- 23 1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación
24 Biomédica de Salamanca, (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca,
25 Spain
- 26 2. Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.
- 27 3. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES),
28 Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain
- 29 4. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón,
30 Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 31 5. Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid,
32 Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
- 33 6. Emergency Department, Hospital General Universitario Gregorio Marañón, Calle del
34 Dr. Esquerdo, 46, 28007 Madrid, Spain.
- 35 7. Microbiology Service, Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012
36 Valladolid, Spain
- 37 8. Viral Infection and Immunity Unit, Centro Nacional de Microbiología, Instituto de
38 Salud Carlos III, Ctra. de Pozuelo, 28, 28222 Majadahonda, Spain
- 39 9. Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain
- 40 10. Servicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Carr.
41 de Alcalá, s/n, 28805, Madrid, Spain
- 42 11. Intensive Care Unit, Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012
43 Valladolid, Spain.

44 12. Emergency Department, Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012
45 Valladolid, Spain.

46 13. Intensive Care Unit, Hospital Clínico Universitario de Valladolid. Av. Ramón y Cajal,
47 3, 47003 Valladolid, Spain

48 14. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y
49 Cajal, 7, 47005 Valladolid, Spain.

50 15. Anesthesiology and Reanimation Service, Hospital Universitario Río Hortega, Calle
51 Dulzaina, 2, 47012 Valladolid, Spain.

52 16. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr.
53 Esquerdo, 46, 28007 Madrid, Spain.

54 17. Microbiology Service, Hospital Clínico Universitario de Valladolid, Av. Ramón y
55 Cajal, 3, 47003 Valladolid, Spain.

56 18. Pulmonology Service, Hospital Universitario y Politécnico de La Fe, Avinguda de
57 Fernando Abril Martorell, 106, 46026, Valencia Spain

58 19. Clinical Microbiology Department. Complejo Asistencial Universitario de León. Calle
59 Altos de nava, s/n, 24001 León, Spain.

60 20. Microbiology Service, Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006
61 Burgos, Spain

62 21. Intensive Care Unit. Complejo Asistencial Universitario de León. Calle Altos de nava,
63 s/n, 24001 León, Spain.

64 22. Pneumology Service, Hospital Universitario Río Hortega / Biomedical Engineering
65 Group, Universidad de Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain.

66 23. Intensive Care Unit. Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006
67 Burgos, Spain.

68 24. Clinical Analysis Service. Hospital Clínico Universitario de Valladolid, Av. Ramón y
69 Cajal, 3, 47003 Valladolid, Spain

70 25. Department of Microbiology and Immunology, Faculty of Medicine, Canadian Center
71 for Vaccinology CCfV, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada

72 26. Laboratory of Immunity, Shantou University Medical College, 22 Xinling Rd, Jinping,
73 Shantou, Guangdong, China.

74 27. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid.
75 Av. Ramón y Cajal, 3, 47003 Valladolid, Spain

76 28. Infectious diseases clinic, Internal Medicine Department, Hospital Universitario Río
77 Hortega, Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain

78 29. Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona,
79 Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036
80 Barcelona, Spain.

81 30. Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research
82 Group, Vall d'Hebron Institut de Recerca, Passeig de la Vall d'Hebron, 119, 08035
83 Barcelona, Spain.

84 31. Respiratory Department, Institut Recerca Biomedica de Lleida, Av. Alcalde Rovira
85 Roure, 80, 25198 Lleida, Spain.

86 **Corresponding author:** David J Kelvin Department of Microbiology and Immunology,
87 Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada. E-mail address:

88 dkelvin@jidc.org.

89 Abstract

90 **Background:** COVID-19 can course with respiratory and extrapulmonary disease. SARS-
91 CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe
92 COVID-19 is characterised by a dysregulated host response to this virus. We studied
93 whether viral RNAemia or viral RNA load in plasma are associated to severe COVID-19
94 and also to this dysregulated response.

95 **Methods:** 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalised
96 ward patients, and 100 critically ill). Viral RNA detection and quantification in plasma was
97 performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2
98 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load
99 in plasma with severity was evaluated by multivariate logistic regression. Correlations
100 between viral RNA load and biomarkers evidencing dysregulation of host response were
101 evaluated by calculating the Spearman correlation coefficients.

102 **Results:** the frequency of viral RNAemia was higher in the critically ill patients (78%)
103 compared to ward patients (27%) and outpatients (2%) ($p < 0.001$). Critical patients had
104 higher viral RNA loads in plasma than non-critically ill patients, with non survivors
105 showing the highest values. When outpatients and ward patients were compared, viral
106 RNAemia did not show significant associations in the multivariate analysis. In contrast,
107 when ward patients were compared with ICU patients, both viral RNAemia and viral RNA
108 load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92
109 [1.183 - 12.968], 0.025), viral RNA load (N1) (1.962 [1.244 - 3.096], 0.004); viral RNA
110 load (N2) (2.229 [1.382 - 3.595], 0.001). Viral RNA load in plasma correlated with higher
111 levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory
112 response (IL-6, CRP, Ferritin), activation of NK cells (IL-15), endothelial dysfunction
113 (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue

114 damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-
115 CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia).

116 **Conclusions:** SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to
117 critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of
118 dysregulated host responses, suggesting a major role of uncontrolled viral replication in the
119 pathogenesis of this disease.

120 **Key words:** SARS-CoV-2, cytokine, sepsis, COVID-19, plasma, RNAemia, viral RNA
121 load, ICU

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139 **Background**

140 With well over 43 million cases and 1.56212 deaths globally, Coronavirus disease 2019
141 (COVID-19) has become the top economic and health priority worldwide [1]. Among
142 hospitalized patients, around 10–20% are admitted to the intensive care unit (ICU), 3–10%
143 require intubation and 2–5% die [2]. SARS-CoV-2 RNA is commonly detected in
144 nasopharyngeal swabs; however viral RNA can be found in sputum, lung samples,
145 peripheral blood, serum, stool samples, and to a limited extent urine [3] [4] [5] [6]. While
146 the lungs are most often affected, severe COVID-19 also induce inflammatory cell
147 infiltration, haemorrhage, and degeneration or necrosis in extra-pulmonary organs (spleen,
148 lymph nodes, kidney, liver, central nervous system) [7] [8]. Patients with severe COVID-
149 19 show signatures of dysregulated response to infection, with immunological alterations
150 involving moderate elevation of some cytokines and chemokines such as IL-6, IL-10 or
151 CXCL10, deep lymphopenia with neutrophilia, systemic inflammation (elevation of C
152 Reactive Protein, ferritin), endothelial dysfunction, coagulation hyper-activation (D-
153 dimers) and tissue damage (LDH) [9] [10] [11] [12] [13] [14].

154 Our hypothesis is that systemic distribution of the virus or viral components could be
155 associated to the severity of COVID-19, and, in turn to a number of parameters indicating
156 the presence of a dysregulated response to the infection.

157 While the SARS-CoV-2 virus has been reported to be difficult to culture from blood [4],
158 PCR based methods are able to detect and quantify the presence of genomic material of the
159 virus in serum or plasma, representing an useful approach to evaluate the impact of the
160 extrapulmonary dissemination of viral material on disease severity and also on the host
161 response to the infection [5] [15]. An excellent approach for achieving absolute
162 quantification of viral RNA load is droplet digital PCR (ddPCR). ddPCR is a next-

163 generation PCR method, which offers absolute quantification with no need of standard
164 curve and greater precision and reproducibility than currently available qRT-PCR methods,
165 as revised elsewhere [16].

166 We employed here ddPCR to detect and quantify viral RNA in plasma from COVID-19
167 patients discharged from the emergency room with mild severity, patients admitted to the
168 ward with moderate severity, and critically ill patients. Our objectives in this study were:
169 1) to evaluate if there is an association between SARS-CoV-2 RNAemia and viral RNA
170 load with moderate disease; 2) to evaluate if there is an association between SARS-CoV-2
171 RNAemia and viral RNA load with critical illness; 3) to evaluate the correlations between
172 SARS-CoV-2 RNA load in plasma and parameters of dysregulated host responses against
173 SARS-CoV-2.

174

175

176

177

178

179

180

181

182

183

184 **Methods**

185 **Study design:** 250 adult patients with a positive nasopharyngeal swab polymerase chain
186 reaction (PCR) test for SARS-CoV-2 performed at participating hospitals were recruited
187 during the first pandemic wave in Spain from March 16th to the 15th of April 2020. The
188 patients recruited were of three different categories. The first corresponded to patients
189 examined at an emergency room and discharged within the first 24 hours (outpatients
190 group, n=50). The second group were patients hospitalized to pneumology, infectious
191 diseases or internal medicine wards (wards group, n=100). Patients who required critical
192 care or died during hospitalization were excluded from this group, in order to have a group
193 of clear moderate severity. The third group corresponded to patients admitted to the ICU
194 (n=100). Patient`s recruited by participating hospital are detailed in the additional file 1.
195 20 healthy blood donors were included as controls. These controls were recruited during
196 the pandemics, in parallel to the SARS-CoV-2 infected patients, and were negative for
197 SARS-CoV-2 IgG. This study was registered at Clinicaltrials.gov with the identification
198 NCT04457505.

199 **Blood samples:** Plasma from blood collected in EDTA tubes samples was obtained from
200 the three groups of patients in the first 24 hours following admission to the emergency
201 room, to the ward, or to the ICU, at a median collection day since disease onset of 7, 8 and
202 10 respectively, and also. from 20 blood donors (10 men and 10 women).

203 **Biomarker profiling:** a panel of biomarkers was profiled by using the Ella-SimplePlex™
204 immunoassay (San Jose, California, U.S.A), informing of the following biological
205 functions potentially altered in severe COVID-19, based in the available evidence on
206 COVID-19 physiopathology [13] [17] and also in our previous experience on emerging
207 infections and sepsis [18] [19] [20] [21]: neutrophil degranulation: Lipocalin-2/NGAL,
208 myeloperoxidase; endothelial dysfunction: ICAM-1, VCAM-1/CD106, Angiopoietin 2; T

209 cell survival and function: IL-7, Granzyme B; immunosuppression: IL-1ra, B7-H1/PD-L1,
210 IL-10; chemotaxis: CXCL10/IP10, CCL2; Th1 response: Interleukin 1 beta, IFN- γ , IL-
211 12p70, IL-15, TNF- α , IL-2; Th2 response: IL-4, IL-10; Th17 response: IL-6, IL-17A;
212 granulocyte mobilization / activation: G-CSF, GM-CSF; coagulation activation: D-Dimer;
213 acute phase reactants: Ferritin (C Reactive protein and LDH were profiled in each
214 participant hospital by their central laboratories).

215 **Detection and quantification of SARS-CoV-2 RNA in plasma:** RNA was extracted from
216 100 μ l of plasma using an automated system, eMAG® from bioMérieux® (Marcy l'Etoile,
217 France). Detection and quantification of SARS-CoV-2 RNA was performed in five μ l of
218 the eluted solution using the Bio-Rad SARS-CoV-2 ddPCR kit according to
219 manufacturer's specifications on a QX-200 droplet digital PCR platform from the same
220 provider. This PCR targets the N1 and N2 regions of the viral nucleoprotein gene and also
221 the human ribonuclease (RNase) P gene using the primers and probes sets detailed in the
222 CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel [22].
223 Samples were considered positive for SARS-CoV-2 when N1 and/or N2 presented values
224 ≥ 0.1 copies/ μ L in a given reaction. RNase P gene was considered positive when it
225 presented values ≥ 0.2 copies/ μ L, following manufacturer's indications. The test was only
226 considered valid when RNase P gene was positive. Final results were given in copies of
227 cDNA / mL of plasma. IgG specific for the Nucleocapsid Protein of SARS-CoV-2 was
228 detected in 150 μ l of plasma using the Abbott Architect SARS-CoV-2 IgG Assay (Illinois,
229 U.S.A). Viral RNA and SARS-CoV-2 IgG were profiled in the same plasma sample.

230 **Statistical analysis:** For the demographic and clinical characteristics of the patients, the
231 differences between groups were assessed using the Chi-square test / Fisher's Exact Test
232 where appropriated for categorical variables. Differences for continuous variables were
233 assessed by using the Kruskal-Wallis test with post hoc tests adjusting for multiple

234 comparisons. Multivariate logistic regression analysis was employed to evaluate the
235 association between viral RNAemia and viral RNA load in plasma with severity, in the
236 comparisons [outpatients vs ward patients] and [ward patients vs ICU patients]. Variables
237 showing significant differences between groups in each comparison in the Kruskal-Wallis
238 test were further introduced in the multivariate analysis as adjusting variables. The list of
239 variables considered as potential adjusting variables were [Age (years)], [Sex (male)],
240 [Alcoholism], [Smoker], [Drug abuse], [Cardiac disease], [Chronic vascular disease],
241 [COPD], [Asthma], [Obesity], [Hypertension], [Dyslipidemia], [Chronic renal disease],
242 [Chronic hepatic disease], [Neurological disease], [HIV], [Autoimmune disease], [Chronic
243 inflammatory bowel disease], [Type 1 diabetes], [Type 2 diabetes], [Cancer], [Invasive
244 mechanical ventilation], [Non-invasive mechanical ventilation], [SARS-CoV-2 IgG],
245 [Temperature (°C)], [Systolic Pressure (mmHg)], [Oxygen saturation (%)], [Bilateral
246 pulmonary infiltrate], [Glucose (mg/dl)], [Creatinine (mg/dl)], [Na (mEq/L)], [K
247 (mEq/L)], [Platelets (cell x 10³ / µl)], [INR], [D Dimer (pg/ml)], [LDH (UI/L)], [GPT
248 (UI/L)], [Ferritin (pg/ml)], [CRP (mg/dl)], [Haematocrit (%)], [Lymphocytes (cells/mm³)],
249 [Neutrophils (cells/mm³)], [Monocytes (cells/mm³)]. Multivariate logistic regression
250 analysis was performed using the “Enter” method, but also the backward stepwise
251 selection method (Likelihood Ratio) was employed in each case to confirm the association
252 between viral RNAemia and viral RNA load in plasma with disease severity (pin < 0.05,
253 pout < 0.10), not forcing entry of these variables in the model. Correlation analysis were
254 performed using the Spearman test applying the Bonferroni correction of the *p* value.
255 Variables evaluated for correlation with viral RNA load were: [Temperature (°C)],
256 [Systolic Pressure (mmHg)], [Oxygen saturation (%)], [Lymphocytes (cells/mm³)],
257 [Neutrophils (cells/mm³)], [Monocytes (cells/mm³)], [Creatinine (mg/dl)], [LDH (UI/L)],
258 [GPT (UI/L)], [Platelets (cell x 10³ / µl)], [INR], [CRP (mg/dl)], and all the biomarkers

259 analyzed by Ella- SimplePlex. Statistical analysis was performed with IBM SPSS® version
260 20 (IBM, Armonk, New York, USA).

261 **Results**

262 **Clinical characteristics of the patients** (Table 1): Patients requiring hospitalization
263 (either general ward or ICU) were older than those patients discharged to their home from
264 the ER. Critically ill patients were more frequently male than those in the other groups.
265 Comorbidities of obesity, hypertension, dyslipidemia and type 2 diabetes were more
266 commonly found in patients requiring hospitalization, with no significant differences found
267 in the comorbidities profile between critically ill and non-critically ill hospitalized patients.
268 14% of the patients in clinical wards required non-invasive mechanical ventilation, while
269 96% of the patients admitted to the ICU required invasive mechanical ventilation.
270 Critically ill patients had increased glucose levels, along with higher concentration of
271 neutrophils in blood, increased levels of ferritin and C-reactive protein (denoting activation
272 of the systemic inflammatory response). Increased levels of INR and D-dimers (reflecting
273 activation of the coagulation system), as well as LDH and GPT, which levels raise as
274 consequence of tissue and liver damage, were also observed in critically ill patients.
275 Patients admitted to the ICU also showed a lower haematocrit, pronounced lymphopenia
276 and lower monocyte counts at admission. ICU patients stayed longer in the hospital than
277 ward patients, with 49 % having a fatal outcome.

278 **Viral RNAemia, viral RNA load in plasma and specific SARS-Cov-2 IgG in the three**
279 **groups of patients.** As depicted in table 1, the frequency of the detection of SARS-CoV-2
280 viral RNA (RNAemia) was significantly higher in the critically ill patients (78%)
281 compared to ward patients (27%) and outpatients (2%) ($p<0.001$). Similarly, the group of
282 critically patients showed higher viral RNA loads in plasma than either ward or outpatients
283 ($p<0.001$) (Table 1 and Figure 1). Non survivors showed the highest concentrations of viral

284 RNA in plasma: viral RNA load (N1 region) in ICU non survivors: 1587 copies / ml
285 [10248]; viral RNA load (N1 region) in ICU survivors 574 copies / mL [1872] (results
286 expressed as median [interquartile rank]); viral RNA load (N2 region) in ICU non
287 survivors: 2798 copies / ml [12012]; viral RNA load (N2 region) in ICU survivors 523
288 copies / mL [1478]. Patients admitted to the wards showed a significant higher frequency
289 of viral RNAemia than outpatients, but viral RNA loads were not significantly different
290 with the latter group (Table 1 and Figure 1). Critically ill patients also had a higher
291 frequency of specific SARS-CoV-2 IgG responses than the other groups (70% in ICU
292 compared to 52% and 49% in the outpatients and ward groups, $p < 0.05$, table 1). No
293 significant differences were found between the group of outpatients and those admitted to
294 the ward. The prevalence of viral RNAemia did not differ between those patients testing
295 positive and those testing negative for SARS-CoV-2 IgG (43.8 % and 40.4 % respectively,
296 $p = 0.586$), who in addition showed no differences in viral RNA load (data not shown).
297 Patients with viral RNAemia showed no differences in the days since onset of symptoms
298 compared to those with no viral RNAemia (8.0 days [6.0]; 8.0 days [7.2], $p = 0.965$). In
299 contrast, samples from patients with SARS-CoV-2 IgG were collected later since disease
300 onset than those without SARS-CoV-2 IgG (10.0 days [7]; 7.0 days [6.0], $p = 0.003$)

301 **Multivariate analysis to evaluate the association between viral RNAemia and viral**
302 **RNA load in plasma with moderate disease and critical illness.** While the proportion of
303 patients with viral RNAemia was higher in the wards group compared to the outpatients'
304 group (table 1), the multivariate analysis did not show a significant association between the
305 presence of viral RNAemia and being hospitalised at the ward, with none of the both
306 methods employed (Additional files 2 and 3). In contrast, when the ward group was
307 compared with critically ill patients, a significant direct association was found between

308 viral RNAemia and viral RNA load in critically ill patients, using the “Enter” method
309 (Table 2) but also the backward stepwise selection method (additional file 4).

310 **Correlations between viral RNA load in plasma and biological responses to SARS-**
311 **CoV-2 infection:** viral RNA load in plasma (targeting either the N1 and the N2 regions)
312 showed the strongest direct correlations with plasma levels of CXCL10, LDH, IL-10, IL-6,
313 IL-15, myeloperoxidase and CCL-2 (MCP-1) and inverse correlations with lymphocytes,
314 monocytes and O₂ saturation (Figure 2). These were the parameters whose levels varied
315 the most in critically patients compared with ward and outpatient groups (Figures 3 and 4
316 and additional file 5). CXCL10 was the most accurate identifier of viral RNAemia in
317 plasma (area under the curve (AUC), [CI95%], p) = 0.85 [0.80 – 0.89], <0.001), and IL-15
318 was the cytokine which most accurately differentiated clinical ward patients from ICU
319 patients (AUC: 0.82 [0.76 – 0.88], <0.001). Plasma viral RNA load also showed significant
320 direct correlations with levels of VCAM-1, PDL-1, GM-CSF, G-CSF, neutrophil counts,
321 IL-1ra, CRP, INR, D-dimer, TFN α , Angiopoietin-2, GPT, ICAM-1, IL-7 and Ferritin
322 (Figure 2), with most of these mediators showing the highest variations in the critically ill
323 patients (Figures 3 and 4 and additional file 5).

324 **Discussion**

325 Our study demonstrates that the presence of SARS-CoV-2-RNA in plasma is associated to
326 critical illness in COVID-19 patients, with the strength of association being the highest in
327 those patients with the highest viral RNA loads. This association was independent of other
328 factors also related to disease severity. Moreover, those critically ill patients who died
329 presented with higher viral RNA loads in plasma than those who survived. SARS-CoV-2
330 viral RNA was detected in the plasma of the vast majority of those COVID-19 patients
331 admitted to the ICU (78%). As far as we know, our study is the largest one to date using
332 ddPCR to quantify SARS-CoV-2 RNA load in plasma from COVID-19 patients, and the

333 only one with a multicentric design. Our results are in consonance with those from Veyer
334 *et al*, who, in a pilot study using this technology, found higher viral RNA loads and a
335 prevalence of RNA viremia of 88% in twenty six COVID-19 patients who were critically
336 ill [16]. The results are also in agreement with those of Hagman *et al*, who, using standard
337 RT-PCR technology, found that the presence of SARS-CoV-2 RNA in serum at hospital
338 admission was associated with a seven-fold increased risk of critical disease and an eight-
339 fold increased risk of death in a cohort of 167 patients hospitalised for COVID-19 [23].

340 Although our study did not determine if the presence of viral RNA in plasma reflects the
341 presence of live virus in peripheral blood, the association found between the presence and
342 concentration of viral RNA in plasma and critical illness suggests that viral replication is
343 more robust in severe COVID-19, and/or that critically ill patients with this disease are not
344 able to control viral replication. This notion is further supported by the correlations found
345 in our study between viral RNA load in plasma and hypercytokinemia involving CXCL10,
346 IL-10, CCL2, IL-6 and IL-15, where the levels of these cytokines were the highest in
347 patients with critical illness. The correlation between viral RNA load and higher levels of
348 cytokines has also been described in the severe infections caused by H5N1 and pandemic
349 H1N1 influenza strains [24] [25]. Active viral replication stimulates the secretion of
350 cytokines by the recognition of viral RNA by endosomal receptors such as toll like
351 receptor 7 (TLR7) in human plasmacytoid dendritic cells and B cells, or TLR8 in myeloid
352 cells [26]. While the elevation of CXCL10, IL-10, CCL2, IL-6 has been extensively
353 documented in severe COVID-19 [9] [10], our work demonstrates a clear correlation
354 between these cytokines and plasma viral load. Furthermore, we report for the first time a
355 major role of IL-15 in severe COVID-19. High levels of IL-15 in critically ill patients with
356 high SARS-CoV-2 RNA load in plasma could be an attempt to stimulate Natural Killer
357 cells to fight the virus [27]. We previously demonstrated that high levels of IL-15, along

358 with IL-6, constituted a signature of critical illness in H1N1 pandemic influenza infection
359 [20].

360 Viral RNA load correlated with higher levels of myeloperoxidase in plasma, which were
361 the highest in those patients admitted to the ICU. This is a marker of neutrophil
362 degranulation and a potent tissue damage factor which has been proposed to play a role in
363 the pathogenesis of ARDS secondary to influenza, by mediating claudin alteration on
364 endothelial tight junctions, eventually leading to protein leakage and viral spread [28]. In
365 this regard, the correlation found between viral RNA load in plasma and higher levels of
366 LDH and GPT could suggest a direct or indirect role of viral replication in mediating tissue
367 destruction in COVID-19.

368 Interesting, but less robust, direct correlations were found between viral RNA load in
369 plasma with GM-CSF and neutrophil counts in blood, further reinforcing the role of
370 neutrophil mediated responses in the pathogenesis of severe COVID-19. The direct
371 correlation with soluble PDL-1 is also relevant, since this the ligand of the inhibitory
372 co-receptor PD1 on T cells, which activation induces anergy of T lymphocytes [29]. This
373 finding reinforces the potential role of immune checkpoint inhibitors in severe COVID-19
374 [30]. In turn, the association found between viral RNA load in plasma and three mediators
375 of endothelial dysfunction (VCAM-1, angiopoietin 2 and ICAM-1), and with coagulation
376 activation markers (D-dimers and INR prolongation) suggests a potential virally linked
377 mechanism in the pathogenesis of endothelitis and thrombosis in COVID-19 disease [7].
378 Finally, the correlation with the acute phase reactants CRP and ferritin suggests a
379 connection between shedding of genomic material of the virus to the blood and the
380 induction of a systemic inflammatory response which is observed in those patients needing
381 critical care.

382 The strongest inverse correlations found in our study was between SARS-CoV-2 RNA
383 load in plasma and lymphocyte and monocyte counts in peripheral blood, for which
384 critically ill patients showed the lowest values. Active viral replication could be a
385 precipitating event in the pathogenesis of lymphopenia and monocytopenia in severe
386 COVID-19 patients [11] [31], by mediating direct cytopathic actions or stimulating the
387 migration of these cells to the extravascular space to reach the infected tissues [32].

388 A limitation of our work is its observational nature, which precludes to infer causality.
389 Nonetheless, the observed associations could serve as hypothesis generators, leading to the
390 development of animal models to confirm the potential link between SARS-CoV-2
391 replication and the dysregulated host responses observed in severe COVID-19.

392 **Conclusion:**

393 Presence of SARS-CoV-2 RNA in plasma is associated with critical illness in patients with
394 COVID-19. The strength of this association increases with viral RNA load in plasma,
395 which in turn correlates with key signatures of dysregulated host response in COVID-19
396 (figure 5). Our findings suggest a major role of uncontrolled viral replication in the
397 pathogenesis of this disease. Assessment of viral RNAemia and viral RNA load in plasma
398 could be useful to early detect those patients at risk of clinical deterioration, to assess
399 response to treatment and to predict disease outcome.

400 **List of abbreviations**

401 SARS-CoV-2: Severe acute Respiratory Syndrom-Coronavirus-2

402 LDH: Lactate dehydrogenase

403 G-CSF: Granulocyte colony-stimulating factor

404 TLR: toll like receptor

405 **Declarations**

406 **Ethics approval and consent to participate:** The study was approved by the Committee
407 for Ethical Research of the coordinating institution, “Comite de Etica de la Investigacion
408 con Medicamentos del Area de Salud de Salamanca”, code PI 2020 03 452. Informed
409 consent was obtained orally when clinically possible. In the remaining cases, the informed
410 consent waiver was authorized by the Ethics committee.

411 **Consent for publication:** not applicable

412 **Availability of data and materials:** the datasets generated and/or analysed during the
413 current study are not publicly available since they are still under elaboration for publication
414 by the authors but are available from the corresponding author on reasonable request.

415 **Competing interests**

416 The authors declare that they have no competing interests

417 **Funding**

418 This work was supported by awards from the Canadian Institutes of Health Research, the
419 Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR
420 OV2 – 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK),
421 Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the
422 “Subvenciones de concesión directa para proyectos y programas de investigación del virus
423 SARS-CoV2, causante del COVID-19”, FONDO - COVID19, Instituto de Salud Carlos III
424 (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the “Convocatoria
425 extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la
426 financiación de proyectos de investigación en enfermedad COVID-19” (GRS COVID
427 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational

428 Vaccinology and Inflammation. APT was funded by the Sara Borrell Research Grant
429 CD018/0123 funded by Instituto de Salud Carlos III and co-financed by the European
430 Development Regional Fund (A Way to Achieve Europe programme). The funding sources
431 did not play any role neither in the design of the study and collection, not in the analysis, in
432 the interpretation of data or in writing the manuscript.

433 **Authors ‘contribution:** JFBM, DJK, JB, RF, FB, AT and RM designed the study. JFBM
434 and DJK wrote the manuscript and interpreted the data. RA coordinated the clinical study
435 and drafted the figures. MGR, DM, PR, FPG, LT, RLI, EB, CA, JMG, JR, RM, MIF, GM,
436 MGE, DC, FDC, JFR, WT, PGJ, GR, IM, EG,IM, SP, SM, PGO, JAC, TRA, CP, JAB,
437 GR, RH, JB, PE, RC, JA, JGB, NM, NBL, LJV, BFC, MAM recruited the patients and /or
438 collected the clinical data. MDG, AO, RO, LMR and JME performed the assays for the
439 detection of SARS-CoV-2 IgG and viremia. APT, CD and AO developed the ddPCR
440 works; CD and NJ profiled the immunological mediators. SR, AMF and MMF developed
441 the statistical analysis and drafted the figures. AAK, ATO, AM and LF performed the
442 literature search. All authors read and approved the final manuscript.

443

444 **Acknowledgements:** we thank SEIMC-GESIDA Foundation for the scientific sponsoring of
445 this project. We thank also the “Biobanco del Centro de Hemoterapia y Hemodonación de
446 Castilla y León”, which provided the plasma samples used in the healthy control group.

447

448

449

450

451 **References:**

- 452 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
453 Johns Hopkins University (JHU) [Internet]. Available from:
454 <https://coronavirus.jhu.edu/map.html>
- 455 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics
456 of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;
- 457 3. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for
458 clinicians. *Clinical Microbiology and Infection*. Elsevier; 2020;26:842–7.
- 459 4. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and
460 serological investigation of 2019-nCoV infected patients: implication of multiple
461 shedding routes. *Emerging Microbes & Infections*. Taylor & Francis; 2020;9:386–9.
- 462 5. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe
463 Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely
464 Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With
465 Coronavirus Disease 2019. *Clin Infect Dis* [Internet]. [cited 2020 Jul 6]; Available
466 from: <https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa449/5821311>
- 467 6. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease
468 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-
469 March 2020: retrospective cohort study. *BMJ*. 2020;369:m1443.
- 470 7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
471 Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395:1417–8.
- 472 8. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis:
473 observations and hypotheses. *Lancet*. 2020;395:1517–20.
- 474 9. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine
475 elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis,
476 and comparison with other inflammatory syndromes. *The Lancet Respiratory Medicine*
477 [Internet]. Elsevier; 2020 [cited 2020 Oct 21];0. Available from:
478 [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30404-5/abstract](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30404-5/abstract)
- 479 10. Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. A
480 dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat*
481 *Med*. 2020;
- 482 11. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory
483 indexes of severe and non-severe patients infected with COVID-19. *Clin Chim Acta*.
484 2020;509:180–94.
- 485 12. Hupf J, Mustroph J, Hanses F, Evert K, Maier LS, Jungbauer CG. RNA-expression
486 of adrenomedullin is increased in patients with severe COVID-19. *Crit Care*.
487 2020;24:527.

- 488 13. McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune
489 mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. *Lancet*
490 *Rheumatol.* 2020;2:e437–45.
- 491 14. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19:
492 immunopathogenesis and Immunotherapeutics. *Signal Transduct Target Ther.*
493 2020;5:128.
- 494 15. Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, et al. High
495 Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease. *Clin*
496 *Infect Dis.* 2020;
- 497 16. Veyer D, Kernéis S, Poulet G, Wack M, Robillard N, Taly V, et al. Highly sensitive
498 quantification of plasma SARS-CoV-2 RNA sheds light on its potential clinical value.
499 *Clin Infect Dis.* 2020;
- 500 17. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of
501 COVID-19: Current State of the Science. *Immunity.* 2020;52:910–41.
- 502 18. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, et al.
503 Interferon-mediated immunopathological events are associated with atypical innate and
504 adaptive immune responses in patients with severe acute respiratory syndrome. *J Virol.*
505 2007;81:8692–706.
- 506 19. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human
507 immunopathogenesis of severe acute respiratory syndrome (SARS). *Virus Res.*
508 2008;133:13–9.
- 509 20. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez
510 P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe
511 pandemic influenza. *Crit Care.* 2009;13:R201.
- 512 21. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G,
513 et al. Current gaps in sepsis immunology: new opportunities for translational research.
514 *Lancet Infect Dis.* 2019;19:e422–36.
- 515 22. CDC. Information for Laboratories about Coronavirus (COVID-19) [Internet].
516 Centers for Disease Control and Prevention. 2020 [cited 2020 Oct 14]. Available from:
517 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>
- 518 23. Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J, et
519 al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a
520 retrospective cohort study. *Clin Infect Dis.* 2020;
- 521 24. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, et al.
522 Fatal outcome of human influenza A (H5N1) is associated with high viral load and
523 hypercytokinemia. *Nat Med.* 2006;12:1203–7.
- 524 25. Almansa R, Anton A, Ramirez P, Martin-Loeches I, Banner D, Pumarola T, et al.
525 Direct association between pharyngeal viral secretion and host cytokine response in
526 severe pandemic influenza. *BMC Infect Dis.* 2011;11:232.

- 527 26. Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19:
528 a clue from innate immunity. *Immunol Res.* 2020;68:161–8.
- 529 27. Perera P-Y, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in
530 inflammation and immune responses to infection: implications for its therapeutic use.
531 *Microbes Infect.* 2012;14:247–61.
- 532 28. Sugamata R, Dobashi H, Nagao T, Yamamoto K-I, Nakajima N, Sato Y, et al.
533 Contribution of neutrophil-derived myeloperoxidase in the early phase of fulminant
534 acute respiratory distress syndrome induced by influenza virus infection. *Microbiol*
535 *Immunol.* 2012;56:171–82.
- 536 29. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-
537 induced immunosuppression. *Nat Rev Nephrol.* 2018;14:121–37.
- 538 30. Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, et al.
539 Immunotherapies for COVID-19: lessons learned from sepsis. *Lancet Respir Med.*
540 2020;
- 541 31. Bermejo-Martin JF, Almansa R, Menendez R, Mendez R, Kelvin DJ, Torres A.
542 Lymphopenic community acquired pneumonia as signature of severe COVID-19.
543 *Journal of Infection.* 2020;
- 544 32. Monneret G, Cour M, Viel S, Venet F, Argaud L. Coronavirus disease 2019 as a
545 particular sepsis: a 2-week follow-up of standard immunological parameters in critically
546 ill patients. *Intensive Care Med.* 2020;46:1764–5.

547

548

549

550 **Conflicts of interests:** the authors declare no conflicts of interests regarding this

551 submission

552

		Outpatients (1)	Ward (2)	ICU (3)	p value (1 vs 2)	p value (1 vs 3)	p value (2 vs 3)
Characteristics	Age [years, median (IQR)]	48.50 [19]	64 [20]	66 [19]	< 0.001	< 0.001	n.s.
	Male [% (n)]	46 (23)	50 (50)	64 (64)	n.s.	0.035	0.046
Comorbidities, [% (n)]	Alcoholism	2 (1)	0 (0)	1 (1)	n.s.	n.s.	n.s.
	Smoking	4 (2)	5 (5)	6 (6)	n.s.	n.s.	n.s.
	Drug abuse	2 (1)	0 (0)	0 (0)	n.s.	n.s.	n.a.
	Cardiac disease	4 (2)	13 (13)	9 (9)	n.s.	n.s.	n.s.
	Chronic vascular disease	2 (1)	2 (2)	5 (5)	n.s.	n.s.	n.s.
	COPD	2 (1)	2 (2)	3 (3)	n.s.	n.s.	n.s.
	Asthma	8 (4)	6 (6)	2 (2)	n.s.	n.s.	n.s.
	Obesity	4 (2)	26 (26)	26 (26)	0.001	0.001	n.s.
	Hypertension	24 (12)	44 (44)	45 (45)	0.017	0.012	n.s.
	Dyslipidemia	16 (8)	41 (41)	34 (34)	0.002	0.021	n.s.
	Chronic renal disease	2 (1)	3 (3)	3 (3)	n.s.	n.s.	n.s.
	Chronic hepatic disease	2 (1)	0 (0)	3 (3)	n.s.	n.s.	n.s.
	Neurological disease	0 (0)	6 (6)	3 (3)	n.s.	n.s.	n.s.
	HIV	0 (0)	0 (0)	1 (1)	n.a.	n.s.	n.s.
	Autoimmune disease	2 (1)	1 (1)	1 (1)	n.s.	n.s.	n.s.
	Chronic inflammatory bowel disease	0 (0)	2 (2)	1 (1)	n.s.	n.s.	n.s.
	Type 1 diabetes	0 (0)	0 (0)	3 (3)	n.a.	n.s.	n.s.
	Type 2 diabetes	0 (0)	23 (23)	22 (22)	< 0.001	< 0.001	n.s.
	Cancer	6 (3)	2 (2)	1 (1)	n.s.	n.s.	n.s.
Treatment during hospitalization, [% (n)]	Invasive mechanical ventilation	0 (0)	0 (0)	96 (96)	n.a.	< 0.001	< 0.001
	Non-invasive mechanical ventilation	0 (0)	14 (14)	34 (34)	0.004	< 0.001	0.002
	Hydroxychloroquine	77.6 (38)	89 (89)	99 (99)	n.s.	< 0.001	0.003
	Chloroquine	4.1 (2)	7 (7)	0 (0)	n.s.	0.042	0.007
	Corticoids	6.7 (3)	29 (29)	85 (85)	0.002	< 0.001	< 0.001
	Azithromycin	15.9 (7)	84 (84)	84 (84)	< 0.001	< 0.001	n.s.
	Remdesivir	0 (0)	1 (1)	9 (9)	n.s.	0.029	0.009
	Tocilizumab	0 (0)	13 (13)	33 (33)	0.008	< 0.001	0.001
	Lopinavir/ritonavir	74 (37)	35 (35)	96 (96)	< 0.001	< 0.001	< 0.001
Beta Interferon	0 (0)	0 (0)	55 (55)	n.a.	< 0.001	< 0.001	
Time course and outcome	Hospital stay [days, median, (IQR)]	-	9 (6)	24 (19)	n.a.	n.a.	< 0.001
	Viral RNAemia [% (n)]	2 (1)	27 (27)	78 (78)	< 0.001	< 0.001	< 0.001
	Viral RNA load in plasma (N1) (copies / mL, median, (IQR))	0 (0)	0 (91)	829 (4444)	n.s.	< 0.001	< 0.001
	Viral RNA load in plasma (N2) (copies / mL, median, (IQR))	0 (0)	0 (93)	836 (4939)	n.s.	< 0.001	< 0.001
	SARS-CoV-2 IgG, [% (n)]	52 (26)	49 (49)	70 (70)	n.s.	0.030	0.002
	Hospital mortality, [% (n)]	0 (0)	0 (0)	49(49)	n.a.	< 0.001	< 0.001
Vital signs	Temperature (°C) [median (IQR)]	36.50 (1.0)	36.80 (1.4)	37.00 (1.4)	-	-	-
	Systolic Pressure (mmHg) [median (IQR)]	120 (29)	126 (25)	120 (26)	n.s.	n.s.	0.001
	Oxygen saturation (%) [median (IQR)]	96 (3)	94 (5)	92 (6)	0.002	< 0.001	0.002

Measurements at diagnosis	Pulmonary infiltrate [% (n)]	72 (36)	93 (93)	100 (100)	< 0.001	< 0.001	0.007
	Bilateral pulmonary infiltrate [% (n)]	26 (13)	67 (67)	93 (93)	< 0.001	< 0.001	< 0.001
	Glucose (mg/dl) [median (IQR)]	99.5 (22)	112 (31)	160.50 (83)	< 0.001	< 0.001	< 0.001
	Creatinine (mg/dl) [median (IQR)]	0.84 (0.18)	0.91 (0.33)	0.88 (0.57)	-	-	-
	Na (mEq/L) [median (IQR)]	138 (4)	138 (5)	138.50 (7)	-	-	-
	K (mEq/L) [median (IQR)]	3.90 (0.50)	4.10 (0.68)	3.95 (0.90)	-	-	-
	Platelets (cell x 10 ³ / μl) [median (IQR)]	223 [97]	207 [113]	204 [126]	-	-	-
	INR [median (IQR)]	1.04 (0.10)	1.11 (0.13)	1.22 (0.22)	0.004	< 0.001	< 0.001
	D Dimer (pg/ml) [median (IQR)]	795278 [828234]	1597362 [2024704]	6182104 [52690922]	< 0.001	< 0.001	< 0.001
	LDH (UI/L) [median (IQR)]	214 (73)	278 (138)	496 (285)	0.002	< 0.001	< 0.001
	GPT (UI/L) [median (IQR)]	27 (43)	29 (29)	44 (44.50)	n.s.	0.021	0.001
Measurements at diagnosis	Ferritin (pg/ml) [median (IQR)]	359507 [458748]	523805 [534757]	923687 [1526492]	n.s.	< 0.001	0.002
	CRP (mg/dl) [median (IQR)]	1.40 (3.50)	40.90 (89.18)	91 (182.10)	< 0.001	< 0.001	0.031
	Haematocrit (%) [median (IQR)]	43.15 (4.72)	42.50 (6.50)	38.15 (6.48)	n.s.	< 0.001	< 0.001
	WBC (cells/mm ³) [median (IQR)]	6450 (2815)	7005 (4115)	9145 (6613)	n.s.	< 0.001	0.006
	Lymphocytes (cells/mm ³) [median (IQR)]	1400 (805)	1000 (433)	540 (445)	0.006	< 0.001	< 0.001
	Neutrophils (cells/mm ³) [median (IQR)]	4260 (2625)	5250 (3918)	8300 (5880)	n.s.	< 0.001	< 0.001
Monocytes (cells/mm ³) [median (IQR)]	500 (300)	400 (300)	300 (280)	n.s.	< 0.001	< 0.001	

553

554 **Table 1: Clinical characteristics of the patients:** continuous variables are represented
555 as [median, (interquartile range, IQR)]; categorical variables are represented as [%,
556 (n)].; INR, International Normalized Ratio; n.s., not significant; n.a., not applicable.
557 COPD (Chronic obstructive pulmonary disease), HIV (Human Immunodeficiency
558 Virus), INR (International Normalized Ratio), LDH (Lactic Acid Dehydrogenase), GPT
559 (glutamic-pyruvate transaminase); CRP (C-reactive protein), WBC (white blood cell).

560

561

562

563

	OR [CI95%]	<i>p</i>	OR [CI95%]	<i>p</i>	OR [CI95%]	<i>p</i>
Sex (male)	2.055 [0.656 - 6.432]	0.216	1.647 [0.508 - 5.337]	0.406	1.608 [0.500 - 5.166]	0.425
Systolic Pressure (mmHg)	0.985 [0.960 - 1.011]	0.253	0.984 [0.958 - 1.011]	0.247	0.984 [0.957 - 1.012]	0.261
O2 Saturation (%)	1.069 [0.986 - 1.160]	0.107	1.076 [0.992 - 1.167]	0.079	1.082 [0.993 - 1.180]	0.071
Bilateral pulmonary infiltrate	2.343 [0.469 - 11.707]	0.300	3.088 [0.566 - 16.852]	0.193	3.064 [0.539 - 17.430]	0.207
Glucose (mg/dl)	1.008 [1.001 - 1.015]	0.028	1.007 [1.000 - 1.015]	0.061	1.007 [0.999 - 1.014]	0.070
INR	1.123 [0.433 - 2.915]	0.812	1.245 [0.469 - 3.305]	0.661	1.377 [0.519 - 3.657]	0.521
D-dimer (pg/mL)	1.000 [1.000 - 1.000]	0.294	1.000 [1.000 - 1.000]	0.190	1.000 [1.000 - 1.000]	0.420
LDH (UI/L)	1.009 [1.004 - 1.014]	0.000	1.008 [1.003 - 1.013]	0.002	1.009 [1.004 - 1.014]	0.001
GPT (UI/L)	1.005 [0.992 - 1.019]	0.443	1.005 [0.991 - 1.019]	0.516	1.006 [0.992 - 1.021]	0.402
Ferritin (pg/mL)	1.000 [1.000 - 1.000]	0.705	1.000 [1.000 - 1.000]	0.856	1.000 [1.000 - 1.000]	0.835
CRP (mg/dl)	0.998 [0.992 - 1.003]	0.420	0.999 [0.993 - 1.005]	0.749	0.998 [0.993 - 1.004]	0.547
Haematocrit (%)	0.770 [0.676 - 0.877]	0.000	0.762 [0.665 - 0.872]	0.000	0.737 [0.633 - 0.858]	0.000
SARS-CoV-2 IgG (Yes)	1.967 [0.627 - 6.170]	0.246	1.835 [0.562 - 5.987]	0.315	1.918 [0.577 - 6.377]	0.288
Lymphocytes (cells/mm ³)	0.998 [0.996 - 1.000]	0.011	0.998 [0.996 - 1.000]	0.012	0.998 [0.996 - 0.999]	0.010
Monocytes (cells/mm ³)	0.998 [0.995 - 1.001]	0.180	0.998 [0.995 - 1.001]	0.212	0.999 [0.996 - 1.002]	0.463
Neutrophils (cells/mm ³)	1.000 [1.000 - 1.000]	0.262	1.000 [1.000 - 1.000]	0.326	1.000 [1.000 - 1.000]	0.239
Viral RNAemia (Yes)	3.916 [1.183 - 12.968]	0.025	-	-	-	-
Viral RNA load (N1) in plasma, log (copies/mL)	-	-	1.962 [1.244 - 3.096]	0.004	-	-
Viral RNA load (N2) in plasma, log (copies/mL)	-	-	-	-	2.229 [1.382 - 3.595]	0.001

564

565 **Table 2: Multivariate logistic regression analysis comparing wards patients against**
566 **critically ill patients (Enter method).** The association between viral RNAemia or viral
567 RNA load targeting the N1 region, or viral RNA load targeting the N2 region with
568 critical illness was evaluated adjusting by major confounding factors.

569


570

571

572

573

574



575

576 **Figure 1: Viral RNA load in plasma, targeting the N1 region (left) and the N2**

577 **region (right), in the three groups of patients. Results are provided as copies of**

578 **cDNA per mL of plasma.**

579

580

581

582

583


584

585

586

587

588



589

590 **Figure 2. Heat map representing the Spearman correlation coefficients between**
 591 **viral RNA load in plasma targeting the N1 and the N2 regions and representative**
 592 **indicators of host dysregulated response.**

593

594


595

596

597

598

599




600

601 **Figure 3. Levels of laboratory parameters indicating host dysregulated response**

602 **across groups.** † indicates significant difference with the healthy control and the bars


603 significant differences between the other groups.

604



605

606 **Figure 4: Levels of laboratory parameters indicating host dysregulated response**
607 **across groups.** † indicates significant difference with the healthy control and the bars
608 significant differences between the other groups.



609

610 **Figure 5: Integrative model depicting the correlations found between the**
611 **indicators of host dysregulated responses and SARS-CoV-2 RNA load in plasma.**

612

613

614

615

616

617

618

619

620

621

Hospital	Outpatients	Wards	ICU
Hospital Clínico Universitario de Valladolid	0	0	45
Hospital General Universitario Gregorio Marañón (Madrid)	44	4	25
Hospital Universitario Infanta Leonor (Madrid)	0	30	0
Hospital Universitario y Politécnico de La Fe (Valencia)	0	27	0
Hospital Universitario Río Hortega (Valladolid)	2	22	23
Hospital Universitario Príncipe de Asturias (Madrid)	4	17	1
Hospital Universitario de Burgos	0	0	2
Hospital Universitario de León	0	0	4
Total	50	100	100

622

623 **Additional file 1: recruited patients in each hospital**

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

	OR [CI 95%]	<i>p</i>
Age (years)	1.071 [1.024 - 1.121]	0.003
Obesity	5.618 [0.841 - 37.552]	0.075
Hypertension	1.024 [0.279 - 3.756]	0.972
Dyslipidemia	1.521 [0.354 - 6.532]	0.573
O2 saturation	1.077 [0.946 - 1.226]	0.261
Bilateral infiltrate	7.652 [2.050 - 28.558]	0.002
Glucose (mg/dl)	1.022 [0.992 - 1.054]	0.156
INR	3.346 [0.121 - 92.829]	0.476
D Dimer (pg/ml)	1.000 [1.000 - 1.000]	0.111
LDH (UI/L)	1.005 [0.998 - 1.012]	0.176
CRP (mg/dl)	1.032 [1.012 - 1.052]	0.002
Lymphocytes (cells/mm ³)	1.000 [0.998 - 1.001]	0.440
Monocytes (cells/mm ³)	0.998 [0.996 - 1.001]	0.223
Neutrophils (cells/mm ³)	1.000 [1.000 - 1.000]	0.382
Viral RNAemia	3.793 [0.344 - 41.845]	0.277

643

644 **Additional file 2. Multivariate logistic regression analysis comparing outpatients**

645 **against wards patients (Enter method).** The association between viral RNAemia with

646 hospitalization at the wards was evaluated adjusting by major confounding factors.

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

	OR [CI95%]	<i>p</i>
Age	1.057 [1.017 - 1.098]	0.005
Obesity	6.675 [1.129 - 39.472]	0.036
Bilateral infiltrate	6.400 [2.153 - 19.024]	0.001
Glucose (mg/dl)	1.027 [0.999 - 1.055]	0.058
CRP (mg/dl)	1.032 [1.013 - 1.051]	0.001
Monocytes (cells/mm ³)	0.997 [0.995 - 1.000]	0.017

662

663

664 **Additional file 3. Multivariate logistic regression analysis comparing outpatients**

665 **against wards patients (backward stepwise selection method / Likelihood Ratio).**

666 The association between viral RNAemia with hospitalization at the wards was evaluated

667 adjusting by major confounding factors, but it was not selected in the final model.

	OR [CI95%]			p	OR [CI95%]			p	OR [CI95%]			p
Systolic Pressure (mmHg)	0.976	0.953	1.000	0.049	0.974	0.949	0.999	0.040	0.974	0.950	0.999	0.042
Glucose (mg/dl)	1.006	1.000	1.012	0.050	1.006	1.000	1.012	0.055	1.005	0.999	1.012	0.088
D-dimer (pg/mL)	1.000	1.000	1.000	0.057	1.000	1.000	1.000	0.025	1.000	1.000	1.000	0.088
LDH (U/L)	1.008	1.004	1.011	0.000	1.006	1.003	1.010	0.001	1.007	1.004	1.011	0.000
Haematocrit (%)	0.798	0.717	0.888	0.000	0.789	0.706	0.881	0.000	0.775	0.688	0.873	0.000
Lymphocytes (cells/mm ³)	0.997	0.996	0.999	0.000	0.997	0.996	0.999	0.000	0.997	0.996	0.999	0.000
Viral RNAemia (Yes)	4.270	1.575	11.580	0.004								
Viral RNA load (N1) in plasma, log (copies/mL)					2.005	1.350	2.978	0.001				
Viral RNA load (N2) in plasma, log (copies/mL)									2.071	1.419	3.022	0.000

668

669 **Additional file 4. Multivariate logistic regression analysis comparing wards**

670 **patients against ICU patients (backward stepwise selection method / Likelihood**

671 **Ratio).** The association between viral RNAemia and viral RNA load with critical illness

672 was evaluated adjusting by major confounding factors.

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

All rights reserved. No reuse allowed without permission.

	Healthy Controls (0)	Outpatients (1)	Ward (2)	ICU (3)	<i>p</i> (0 vs 1)	<i>p</i> (0 vs 2)	<i>p</i> (0 vs 3)	<i>p</i> (1 vs 2)	<i>p</i> (1 vs 3)	<i>p</i> (2 vs 3)
ICAM-1 (pg/ml)	289208 [92857]	358431.50 [88702.30]	377655 [150081.80]	466818 [202189.80]	0.036	< 0.001	< 0.001	n.s.	< 0.001	< 0.001
Lipocalin-2 (pg/ml)	82634.50 [29205.30]	73134.50 [32007.30]	94077 [49868]	100165 [57819.80]	n.s.	n.s.	n.s.	0.011	< 0.001	n.s.
Myeloperoxidase (pg/ml)	27541.50 [12906.80]	41902 [30413.80]	88244.50 [78145]	141971.50 [148623.50]	n.s.	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
VCAM-1 (pg/ml)	618380 [195510.50]	800393 [403378]	1191387 [618827]	1248699.50 [603679]	0.021	< 0.001	< 0.001	< 0.001	< 0.001	n.s.
PD-L1 (pg/ml)	55.85 [33.27]	110.50 [120.68]	178 [114.25]	228 [137.75]	0.031	< 0.001	< 0.001	0.045	< 0.001	0.031
G-CSF (pg/ml)	6.90 [7.67]	23.55 [20.48]	31.95 [42.85]	36.25 [53.35]	< 0.001	< 0.001	< 0.001	n.s.	0.022	n.s.
IL-1b (pg/ml)	0.44 [1.65]	0.16 [0.30]	0.44 [0.53]	0.38 [0.51]	n.s.	n.s.	n.s.	0.005	< 0.001	n.s.
IL-10 (pg/ml)	1.59 [0.48]	4.19 [6.68]	9.11 [10.14]	17 [22.25]	0.002	< 0.001	< 0.001	0.007	< 0.001	< 0.001
IL-17A (pg/ml)	1.95 [1.08]	2.38 [1.45]	2.32 [1.44]	3.06 [2.87]	n.s.	0.047	0.002	n.s.	n.s.	n.s.
GM-CSF (pg/ml)	0.66 [0.42]	1.07 [0.54]	1.10 [0.67]	1.62 [1.01]	n.s.	n.s.	< 0.001	n.s.	< 0.001	< 0.001
IL-7 (pg/ml)	1.81 [1.49]	2.04 [3.12]	3.19 [4.19]	4.84 [5.17]	n.s.	0.009	< 0.001	0.017	< 0.001	n.s.
CXCL10 (pg/ml)	91.9 [71.85]	470.50 [731.50]	977.50 [943]	1609.50 [1693.75]	0.003	< 0.001	< 0.001	0.002	< 0.001	0.003
Angiopoietin-2 (pg/ml)	708 [260.75]	809 [479.75]	1128 [779.50]	1769.50 [2064.25]	n.s.	0.001	< 0.001	0.008	< 0.001	0.001
IL-1ra (pg/ml)	478 [1159.75]	653.50 [1039.25]	1796 [1896]	1634 [4472.50]	n.s.	< 0.001	< 0.001	< 0.001	< 0.001	n.s.
IL-6 (pg/ml)	1.27 [0.83]	6.34 [12.42]	33.25 [48.10]	105.50 [252.23]	0.027	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
CCL2 (pg/ml)	103.50 [39]	189 [157.50]	283.50 [304]	490 [881.75]	0.012	< 0.001	< 0.001	0.031	< 0.001	< 0.001
IL-12p70 (pg/ml)	0.62 [0.71]	1.46 [0.67]	1.51 [0.71]	1.36 [0.94]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	n.s.
IL-2 (pg/ml)	0.02 [0.09]	0.53 [0.39]	0.49 [0.57]	0.63 [0.83]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	n.s.
IL-4 (pg/ml)	0.13 [0.27]	0.33 [0.34]	0.33 [0.39]	0.29 [0.37]	0.021	0.006	0.041	n.s.	n.s.	n.s.
IL-15 (pg/ml)	2.11 [0.54]	3.85 [3.7]	4.89 [2.90]	8.38 [5.19]	0.001	< 0.001	< 0.001	n.s.	< 0.001	< 0.001
Granzyme-B (pg/ml)	12 [15.75]	33.20 [27.92]	46.15 [40.03]	39.25 [35.58]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	0.036
INFγ (pg/ml)	0.68 [0.45]	4.35 [14.16]	7.42 [15.13]	3.44 [8.50]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	0.021

TNFα (pg/ml)	5.11 [1.79]	10.60 [4.18]	13 [6.46]	12.95 [10.34]	< 0.001	< 0.001	< 0.001	0.021	0.006	n.s.
---	----------------	-----------------	--------------	------------------	---------	---------	---------	-------	-------	------

691

692 **Additional file 5. Laboratory parameters ‘levels across groups.**